News with Multimedia

Today is March 19, 2024. All times in Eastern Daylight Time.

Intel Appoints Stacy Smith to Board of Directors

03/13/2024 - 04:30 PM

BUSINESS WIRE
Los estudiantes de Learn4Life exploran vías profesionales para un futuro en el diseño gráfico

03/13/2024 - 04:13 PM

BUSINESS WIRE
Culture Kings Returns as an Official Partner of Rolling Loud California

03/13/2024 - 04:05 PM

BUSINESS WIRE
PagerDuty Appoints Teresa Carlson to Board of Directors

03/13/2024 - 04:05 PM

BUSINESS WIRE
泰雷茲與Neural Labs合作支持人工智能驅動的智慧城市

03/13/2024 - 04:00 PM

BUSINESS WIRE
泰雷兹与Neural Labs合作支持人工智能驱动的智慧城市

03/13/2024 - 04:00 PM

BUSINESS WIRE
loanDepot’s Toy Eng Named Top Producer on State of New York Mortgage Agency’s 2023 Hall of Fame

03/13/2024 - 03:55 PM

BUSINESS WIRE
AEG Presents and Cárdenas Marketing Network Forge Historic Partnership

03/13/2024 - 03:30 PM

BUSINESS WIRE
Erste Dosen von BRUKINSA ® für Patienten mit chronischer lymphatischer Leukämie in Ländern mit niedrigem und mittlerem Einkommen im Rahmen der Zusammenarbeit von The Max Foundation, BeiGene und der BeiGene Foundation

03/13/2024 - 03:01 PM

BUSINESS WIRE
Primeras dosis de BRUKINSA® suministradas a pacientes con leucemia linfocítica crónica en países de renta baja y media en colaboración con The Max Foundation, BeiGene y BeiGene Foundation

03/13/2024 - 03:01 PM

BUSINESS WIRE
Les premières doses de BRUKINSA® sont administrées à des patients atteints de leucémie lymphoïde chronique dans des pays à revenus faibles et moyens, grâce à la collaboration de la Max Foundation, de BeiGene et de la BeiGene Foundation

03/13/2024 - 03:01 PM

BUSINESS WIRE
Brydon Group Announces Strategic Investment in NATA Compliance Services with Appointment of Jiri Marousek as CEO

03/13/2024 - 02:31 PM

BUSINESS WIRE
Resumen: Cybin recibe la designación de terapia innovadora de la FDA para su nueva molécula psicodélica CYB003 y anuncia resultados positivos durante cuatro meses en el trastorno depresivo mayor

03/13/2024 - 02:22 PM

BUSINESS WIRE
Samenvatting: Cybin ontvangt FDA-aanduiding voor baanbrekende therapie voor zijn nieuwe psychedelische molecuul CYB003 en kondigt positieve duurzaamheidsgegevens over vier maanden aan voor depressieve stoornis

03/13/2024 - 02:22 PM

BUSINESS WIRE
Riassunto: Cybin riceve dalla FDA la designazione di terapia innovativa Breakthrough Therapy per la sua nuova molecola psichedelica CYB003 e annuncia dati positivi a quattro mesi per il disturbo depressivo maggiore

03/13/2024 - 02:22 PM

BUSINESS WIRE
Cybin erhält von der FDA den Status eines Therapiedurchbruchs für sein neuartiges psychedelisches Molekül CYB003 und gibt positive Daten zur viermonatigen Dauerhaftigkeit bei schwerer depressiver Störung bekannt

03/13/2024 - 02:22 PM

BUSINESS WIRE
プーマ、2023年に温室効果ガス排出量を24%削減

03/13/2024 - 02:16 PM

BUSINESS WIRE
PUMA 2023年温室气体排放量减少24%

03/13/2024 - 02:14 PM

BUSINESS WIRE
PUMA 2023年溫室氣體排放量減少24%

03/13/2024 - 02:14 PM

BUSINESS WIRE
PUMA reduz as emissões de gases de efeito estufa em 24% em 2023

03/13/2024 - 01:58 PM

BUSINESS WIRE
PUMA reduce un 24 % sus emisiones de gases de efecto invernadero en 2023

03/13/2024 - 01:57 PM

BUSINESS WIRE
Samenvatting: Eerste dosissen BRUKINSA® verstrekt aan patiënten met chronische lymfatische leukemie in lage- en middeninkomenslanden in samenwerking met The Max Foundation, BeiGene en de BeiGene Foundation

03/13/2024 - 01:51 PM

BUSINESS WIRE
Riassunto: Prime dosi di BRUKINSA ® somministrate a pazienti affetti da leucemia linfatica cronica in paesi a basso e a medio reddito grazie alla collaborazione tra The Max Foundation, BeiGene e la fondazione BeiGene

03/13/2024 - 01:51 PM

BUSINESS WIRE
As primeiras doses de BRUKINSA® fornecidas a pacientes com leucemia linfocítica crônica em países de baixa e média renda sob a colaboração da The Max Foundation, BeiGene e BeiGene Foundation

03/13/2024 - 01:50 PM

BUSINESS WIRE
PUMA réduit ses émissions de gaz à effet de serre de 24 % en 2023

03/13/2024 - 01:47 PM

BUSINESS WIRE

1 ... 9 10 11 12 13 14 15 16 17 18 19 ... 120

Next »

Search